Which agent is most appropriate for managing obesity in a patient with newly diagnosed hypertension and a body mass index of 33 kg/m2?

Semaglutide is an appropriate choice for managing obesity in a patient with newly diagnosed hypertension and a body mass index of 33 kg/m² due to its unique mechanism of action and strong efficacy in weight management. Semaglutide mimics the effects of the GLP-1 (glucagon-like peptide-1) hormone, which plays a key role in regulating appetite and food intake. Clinical studies have demonstrated that semaglutide not only promotes significant weight loss but also has a favorable cardiovascular profile, making it particularly beneficial for patients with hypertension or other cardiovascular risk factors.

In contrast, while naltrexone/bupropion, phentermine, and phentermine/topiramate may also aid in weight management, they have limitations. Naltrexone/bupropion is less effective in terms of weight loss and may have contraindications related to hypertension or cardiovascular conditions, as it can increase blood pressure and heart rate. Phentermine, while effective for short-term weight loss, is a stimulant and may not be suitable for patients with significant hypertension due to its potential to elevate blood pressure. Phentermine/topiramate combines the effects of both agents but similarly has stimulant properties that could pose risks for patients with newly diagnosed hypertension.

Therefore